ATE427120T1 - T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten - Google Patents

T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten

Info

Publication number
ATE427120T1
ATE427120T1 AT01127424T AT01127424T ATE427120T1 AT E427120 T1 ATE427120 T1 AT E427120T1 AT 01127424 T AT01127424 T AT 01127424T AT 01127424 T AT01127424 T AT 01127424T AT E427120 T1 ATE427120 T1 AT E427120T1
Authority
AT
Austria
Prior art keywords
cells
spongiform encephalopathy
products
cell
tissue derived
Prior art date
Application number
AT01127424T
Other languages
English (en)
Inventor
Adriano Aguzzi
Michael A Klein
Alex Raeber
Charles Weissmann
Rolf Zinkernagel
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE427120T1 publication Critical patent/ATE427120T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AT01127424T 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten ATE427120T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01127424A EP1214943B1 (de) 1997-12-16 1997-12-16 T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten
EP97122186A EP0931551B1 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Publications (1)

Publication Number Publication Date
ATE427120T1 true ATE427120T1 (de) 2009-04-15

Family

ID=8227810

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte

Country Status (9)

Country Link
US (1) US20080063600A1 (de)
EP (4) EP1214943B1 (de)
JP (1) JP2002508335A (de)
AT (3) ATE420355T1 (de)
AU (1) AU2613199A (de)
CA (1) CA2348660A1 (de)
DE (3) DE69739344D1 (de)
ES (3) ES2324334T3 (de)
WO (1) WO1999030738A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501385A (ja) * 1997-05-30 2002-01-15 ヴァイス ステファン 可溶性ラミニン受容体前駆体及びその相互作用を阻止するための方法
PL200134B1 (pl) 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
EP1921451A3 (de) 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
CA2632662A1 (en) * 2005-12-08 2007-06-14 South Dakota State University Methods of in vitro propagation and detection of infectious prion
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
US20100178293A1 (en) * 2007-06-22 2010-07-15 Olaf Weber Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
KR102509006B1 (ko) * 2017-04-01 2023-03-13 에이브이엠 바이오테크놀로지, 엘엘씨 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273882A (en) 1985-06-13 1993-12-28 Amgen Method and kit for performing nucleic acid hybridization assays
US5055290A (en) 1985-12-18 1991-10-08 Boehringer Mannehim Gmbh Ciamexone as a selective immunosuppressant
EP0420913B1 (de) * 1988-06-14 1995-11-15 Cell Med, Inc. Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren
US5369119A (en) 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
DE852011T1 (de) * 1995-09-14 2001-10-11 Univ California Für natives prp-sc spezifische antikörper
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
EP1044020A2 (de) 2000-10-18
EP0931551A1 (de) 1999-07-28
DE69739210D1 (de) 2009-02-26
EP1214943B1 (de) 2009-04-01
WO1999030738A3 (en) 1999-10-21
ES2285720T3 (es) 2007-11-16
ATE358497T1 (de) 2007-04-15
DE69737557D1 (de) 2007-05-16
AU2613199A (en) 1999-07-05
EP0931551B1 (de) 2007-04-04
JP2002508335A (ja) 2002-03-19
ES2320314T3 (es) 2009-05-21
DE69739344D1 (de) 2009-05-14
US20080063600A1 (en) 2008-03-13
EP1214943A1 (de) 2002-06-19
EP1215497A1 (de) 2002-06-19
DE69737557T2 (de) 2007-12-20
ES2324334T3 (es) 2009-08-05
EP1215497B1 (de) 2009-01-07
CA2348660A1 (en) 1999-06-24
ATE420355T1 (de) 2009-01-15
WO1999030738A2 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
ATE427120T1 (de) T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
CY1107550T1 (el) Συνδυαστικα εμβολια μηνιγγιτιδας b/c
EP0915648A4 (de)
IL186495A (en) Use of disaccharide-based compounds for the manufacture of medicaments without an exogenous antigen for prophylactic and therapeutic treatment of infectious and other diseases
DE69106586T2 (de) Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris.
DE60118743D1 (de) Methode zur behandlung und prävention von ansteckenden krankheiten
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69026506D1 (de) Biologisches präparat und seine verwendung
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
NO912942D0 (no) Vaksine for preventiv behandling av infeksjon av leverikte hos droevtyggere.
ATE281173T1 (de) Behandlung einer virusinfektion bei schweinen
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
FR2712493B1 (fr) Utilisation de photosensibilisateurs dérivés du noyau phorbine pour la décontamination du sang infecté par des parasites et/ou des virus.
ES2137544T3 (es) Procedimiento para la preparacion de un preparado biologico terapeutico sin riesgo de infeccion por virus.
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
DE69808839T2 (de) Makrophagen-stimulierende Protein für Behandlung von Erkrankungen des Nervensystems
Ranieri Notes On Aids In Mexico
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.
RU97104338A (ru) Препарат абактан - композиция для лечения и профилактики инфекционных болезней животных
Kissinger Geneva conference points out problems
DE343258T1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.
ATE76302T1 (de) Verwendung von einer immunstimulanten biologisten substanz zur herstellung eines medikaments zur behandlung des menschlichen immunschwaechevirus.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties